The Paclitaxel (TAXUS™)-Eluting Stent: A Review of its Use in the Management of de novo Coronary Artery Lesions

Authors: John Waugh; Antona J. Wagstaff

Source: American Journal of Cardiovascular Drugs, Volume 4, Number 4, 2004 , pp. 257-268(12)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

The TAXUS^™/Express^2™ stent contains paclitaxel 1 µg/mm². On deployment, paclitaxel is slowly released into the intimal tissue of the coronary artery to prevent cell proliferation and neointimal hyperplasia. When deployed in patients with previously untreated coronary artery lesions, the paclitaxel-eluting stent (PES) effectively reduces the need for revascularization without increasing the risk of in-stent thrombosis. While long-term outcomes data and comparative efficacy and cost-benefit trials versus other drug-eluting stents are required, the PES appears to be an attractive alternative for the management of de novo coronary artery lesions.

Keywords: Adis Drug Evaluations; Ischaemic heart disorders, treatment; Coronary stenting; Coronary interventions; Paclitaxel, therapeutic use; Mitosis inhibitors, therapeutic use

Document Type: Research article

Affiliations: 1: Adis International Inc., Yardley, Pennsylvania, USA

Publication date: 2004-01-01